Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Sorry important bit truncated .
"Concluding Remarks
Liquid biopsies are of growing importance for the management of cancer and in drug development. This sampling technique has multifaceted utility in the patient care pathway and is less invasive, less costly, and is better suited for real-time longitudinal monitoring compared to the current gold standard, tissue biopsy. Liquid biopsies can be implemented in clinical studies as a fast and accurate method for patient cohort stratification, as an early efficacy-response biomarker, for assessment of clonal evolution and the emergence of treatment resistance. CTCs are emerging as a key component of liquid biopsies that can provide additional transcriptomic insight into clinically relevant biomarkers for a more holistic view of disease status. Furthermore, molecular analysis of liquid biopsies is advancing to provide a rapid and increasingly cost-effective method to evaluate clinically actionable information. "
Benefit of using MSK - " Liquid biopsies have specific advantages over the current gold standard for tumour characterisation, tissue biopsies"
Interesting video https://www.mskcc.org/videos/learn-more-about-molecular-diagnostics-service-msk
--------------------------------------
Recent article DDW "Can liquid biopsies transform precision medicine?"
https://www.ddw-online.com/can-liquid-biopsies-transform-precision-medicine-27935-202401/
Challenges in the Oncology Clinical Trials Space
The oncology market is a key growth driver for the pharma industry, with global drug revenues expected to reach US$390 billion by 2027 and the annual number of new cancer cases set to grow from 18 to 27 million by 20401,2. With oncology accounting for a third of pharmaâs product pipeline, significant challenges include fierce competition, high research and development costs over, 10-15 years for clinical development, and pressures to rapidly meet the demand for new treatments2-4. Furthermore, oncology clinical trials are frequently challenged by low enrolment rates, failure to achieve primary endpoints, study design complexity and limited funding5. As such there is a need to develop fast and accurate methods to assess drug safety and efficacy, facilitating early success or failure.
The identification of molecular drivers of cancer and the development of drugs to target these biomarkers, has led to an evolution in clinical trial design. This, coupled with a growing understanding of the heterogeneity of cancer as the basis for treatment resistance, tumour evolution and therefore the main source of therapeutic failure,6 has highlighted the importance of developing personalised therapy. This has facilitated a shift towards biomarker-based studies and data-driven selection of patients based on the likelihood of response to a therapy.7
This evolution in clinical trial design is being influenced by the emergence of fast and cost-effective liquid biopsy technologies, that provide a wealth of longitudinal information on disease status and heterogeneity, tumour evolution over time, response to therapy, development of resistance mechanisms and disease relapse.
A liquid biopsy is a minimally invasive test performed on a body fluid, usually blood, that allows for the isolation and analysis of circulating tumour cells (CTCs), circulating tumour DNA (ctDNA) exosomes, nucleic acids or proteins derived from a patientâs tumour, and provides valuable information for the management of patient care (Figure 1). Liquid biopsies have specific advantages over the current gold standard for tumour characterisat
Thanks GrumpyMan
Just in time for phase 2
https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus#:~:text=The%20goal%20of%20Project%20Optimus%20is%20to%20educate%2C,drug%20but%20the%20safety%20and%20tolerability%20as%20well.
Project Optimus
Purpose
The Oncology Center of Excellence (OCE) Project Optimus is an initiative to reform the dose optimization and dose selection paradigm in oncology drug development. Too often, the current paradigm for dose selectionâbased on cytotoxic chemotherapeuticsâleads to doses and schedules of molecularly targeted therapies that are inadequately characterized before initiating registration trials.
Patients may be receiving these novel therapeutics for longer periods of time to maximize the benefit of a drug, which ideally includes not only longer survival but also an improved quality of life.
Poorly characterized dose and schedule may lead to selection of a dose that provides more toxicity without additional efficacy, severe toxicities that require a high rate of dose reductions, intolerable toxicities that lead to premature discontinuation and missed opportunity for continued benefit from the drug, and potentially persistent or irreversible toxicities that limit the options for receiving benefit of subsequent therapiesâto name a few examples.
Goals
The goal of Project Optimus is to educate, innovate, and collaborate with companies, academia, professional societies, international regulatory authorities, and patients to move forward with a dose-finding and dose optimization paradigm across oncology that emphasizes selection of a dose or doses that maximizes not only the efficacy of a drug but the safety and tolerability as well.
Specific Goals include:
Communicate expectations for dose-finding and dose optimization, through Guidance, workshops, other public meetings
Provide opportunities for and encourage drug developers to meet with FDA Oncology Review Divisions early in their development programs, well before conducting trials intended for registration, to discuss dose-finding and dose optimization.
Develop strategies for dose finding and dose optimization that leverages nonclinical and clinical data in dose selection, including randomized evaluations of a range of doses in trials. An emphasis of such strategies will be placed on performing these studies as early as possible in the development program and as efficiently as possible to bring promising new therapies to patients."
LD seem to be very procative on Linkedin : No idea on product revenues but still a need for rapid tests : LD SAS manufacturer : Anatolia Geneworks
https://www.linkedin.com/feed/update/urn:li:activity:7160276470005645312/
https://www.launchdiagnostics.com/product/anatolia-geneworks-sars-cov-2-pcr-solution/
---------------------------------
"In its latest information bulletin on acute respiratory infections, SantĂŠ Publique France lists a strong flu epidemic with a constant presence of covid and a sharp decrease in RSV cases. The number of visits to the emergency room for flu or influenza-like illness increased by +46% compared to the previous week, the number of hospitalizations is also up (+41%).
In this epidemic context, the use of a combined rapid lateral flow test for influenza A and B and Covid allows rapid identification of positive patients as a first-line treatment and limits the number of tests by molecular biology. A rapid diagnosis in less than 20 minutes leads to better patient care by reducing the risk of complications for the most vulnerable people.
https://lnkd.in/eB4B-eBK
hashtag#grippe hashtag#testrapide hashtag#Covid hashtag#santepubliquefrance
ahs : trinity delta - apply a very modest 10% chance of success for ava6000 . (avacta have already proved pre|cision technolgy works ) even so trinity value avct @ ÂŁ672m (237p/share) :
as others have stated it is the asset ip that is valuable. the unknown part is who/when & how much a major cash rich biotech will pay to get access to this technology . loads of examples out there - some prepared to pay $ billions .
https://*********************/notearticle/article?researchnoteid=33_79f6bd17-a6ac-465f-93fd-44fc35f8a6a2&whitelabelcompanyid=gb00byyw9g87&clearcache=false
https://avacta.com/investors/research-analyst/
-----------------------------------------------------------------
"avacta tailored tumour targetting with pre|cision avactaâs proprietary pre|cision platform is key to the investment case, and further details on lead programme ava6000, a tumour targeted form of the chemotherapy doxorubicin, continue to support key hypotheses. data show that ava6000 is selectively activated at the target tumour site, resulting in lower toxicities, improved tolerability, and greater potency. this has translated into promising, albeit early, signs of clinical activity. ava6000âs clinical success will help to validate pre|cision, and could unlock an extensive opportunity to repurpose a range of proven, but currently sub-optimal, therapies, and alongside the affimer platform, could be used in novel diagnostic and therapeutic applications. ava6000 has now completed the seventh, and final, cohort of the phase ia three-weekly arm, with patient screening started in the two-weekly arm in the us. data will direct the format of a potentially pivotal phase ii trial. news over the next 18-24 months should offer multiple value-inflection points. our updated valuation including the coris acquisition is ÂŁ672m (237p/share). "
Https://annual2024meeting.com/aacr/?msclkid=86d2c48bbfd516cf2fc2a148d59c177a&utm_source=bing&utm_medium=cpc&utm_campaign=destination&utm_term=aacr%202024&utm_content=AACR%205%20April
"AACR 2024
American Association for Cancer Research
San Diego Convention Center,
San Diego, California
05th - 10th April, 2024"
Good Morning : Shareholers indeed owe a debt of gratitude to those very sick patients taking part in Q3W study. "There are several patients still being treated in the Q3W study. " so AVA6000 treatment already providing clinical benefit & one "patient in cohort 3 (UPS) has many more cycles possible which is great to see. " This is just the start. Unfortunately take time but just think "ipre|CISION⢠technology" will be available globally to treat many cancer patients both young & old .
Been said many times . hopefully will be a win/win for everyone involved "patients - clinicians & shareholders " nothing wrong with that and of course many thanks to Avacta ..
Coris team relaxing after a long day presenting @ Arab Health Exhibition
------------
"Awex United Arab Emirates plays a pivotal role in assisting Walloon companies to gain a foothold and expand in the UAE market. Networking events offer a unique opportunity to forge strategic contacts in a multicultural region where face-to-face interactions are crucial.
In continuation of this, the team, along with Flanders Investment & Trade - UAE and hub.brussels, hosted a networking session on Tuesday bringing together dynamic leaders and innovators in healthcare. đ¤đĄ
Our heartfelt thanks to all attendees for their engagement and enthusiasm during this event. đ
https://www.linkedin.com/company/coris-bioconcept/
ld updates
"the global aspergillosis treatment market size was estimated at usd 4.25 billion in 2022 and is expected to grow at a compound annual growth rate (cagr) of 3.99% from 2023 to 2030."
https://www.grandviewresearch.com/industry-analysis/aspergillosis-treatment-market-report
"
launch diagnostics limitedlaunch diagnostics limited
1,429 followers1,429 followers
1d ⢠1d â˘
today is world aspergillosis day. invasive aspergillosis (ia) poses significant challenges in healthcare; seen in immunocompromised patients ia is particularly dangerous and can cause systemic complications throughout the body.
galactomannan testing forms a crucial part of the algorithm for ia diagnosis, with locally available testing offering precise and timely results when compared to often costly referrals.
launch diagnostics and accusay diagnostics are proud to introduce the vircliaÂŽ lotus, a cutting-edge clia platform, combining a portfolio of over 90 tests and features a fully automated galactomannan (gm) ag assay for identifying gm in both serum and bronchoalveolar lavage (bal) samples.
the associated benefits to patient management and outcomes make the vircliaÂŽ lotus gm ag assay a key part of any labs ****nal in the fight against ia infections
for more information, please visit www.launchdiagnostics.com "
-----------
"we're proud to announce the launch of our new website: www.launchdiagnostics.fr for launch diagnostics france sas!
today marks a significant milestone as we extend our online presence to better serve our valued customers and partners in france. our new website offers a user-friendly platform where our french customers can explore our comprehensive range of diagnostic products, services, and resources.
explore our new french website today!
hashtag#diagnostics hashtag#france hashtag#diagnostics hashtag#healthcare hashtag#patientcare hashtag#newwebsite hashtag#diagnosticinnovation launch diagnostics france sas"
Neil Bell here he is !
https://web.archive.org/web/20231003211602/https://avacta.com/therapeutics/therapeutics-team/
Amicable transition .
FYI : "Fiona McLaughlin Chief Scientific Officer, Therapeutics" still shown on picture update today + update Christina Coughlin Head of Research and Development "
https://avacta.com/therapeutics/therapeutics-team/
https://avacta.com/therapeutics/therapeutics-team/ 0 2024-02-02 14:48 +00:00
FYI : Benefits of https://avacta.com/therapeutics/precision/
-------------
MM comments :
"Myles McNulty
@MylesMcNulty
Evidently they (and others) are super interested in FAP as a biomarker in their targeted oncology efforts.
FAP is highly upregulated in the TME, but unlike most biomarkers targeted by ADCs and immunotherapies, itâs primarily found on structures around cancer cells (such as stromal cells), and less so on the actual surfaces of of cancer cells.
This offers two key benefits:
- enables the âbystander effectâ, i.e. destruction of other cells around the cancer cells, as well as possibly encouraging an immune response to assist the drug in its efforts;
- lower probability of the cancer developing resistance to the FAP-targeting drug.
Clearly however, binding to FAP with an antibody sufficiently to cause a therapeutic effect, is proving difficult.
Answer - find a new method of using FAP as a biomarker, but without the need to bind to it.
I introduce
@avacta
âs pre | CISION platform - the linker that is âcleavedâ by FAP, enabling extra cellular release of cytotoxic warheads.
Not that #AVCT will need any instruction to Big Pharma. The worldâs largest players will all have more than one eye on Avacta.
8:22 AM ¡ Feb 2, 2024
¡
632
Views
---------------
Interesting tweet :
https://www.fiercebiotech.com/biotech/roche-pipeline-bulging-deal-spree-axes-8-oncology-and-neurology-programs-speed-rd
"On the oncology side, Roche removed three phase 1 candidates from the pipeline. The drugmaker dealt a second blow to the hopes of treating solid tumors by targeting FAP. Having already stopped studying a FAP-IL-2v candidate, Roche removed the solid tumor FAP-CD40 prospect RG6189 from its pipeline in the fourth quarter. A phase 1b trial of a FAP-4-1BBL candidate, RG7827, is continuing. "
TopG :Thanks for sharing :
Not really sure but this research paper might be connected with AVA=005 ?
"Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk"
https://haematologica.org/article/view/9737
------------
" Hypofibrinolysis is associated with increased risk of atherothrombotic events.1-3 Although most studies have only shown an association between hypofibrinolysis and cardiovascular disease, a more recent longitudinal study in a large population of patients with acute coronary syndrome demonstrated that prolonged fibrin clot lysis is an independent predictor of cardiovascular mortality.4"
LD have some interesting manufactuer products .
https://www.launchdiagnostics.com/manufacturer/fujirebio/
"Launch Diagnostics LimitedLaunch Diagnostics Limited
1,417 followers1,417 followers
17h ⢠17h â˘
At Launch Diagnostics, we are a distributor of Fujirebio products (leaders in testing for Neurodegenerative diseases).
Please visit https://lnkd.in/etfKQG5b or contact your local territory
---------------------
https://www.fujirebio.com/en/about-fujirebio
A proven pioneer and partner to the diagnostics industry
Fujirebio is an R&D-driven company constantly developing new technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care.
Our global teams located in Japan, Asia, Europe and the US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials in order to supply, develop or manufacture diagnostic solutions on a wide variety of platforms. Through this business model, we ensure that the potentially life-changing diagnostic markers meet the largest global need in the shortest possible time."
"
Fujirebio EuropeFujirebio Europe
6,932 followers6,932 followers
22h ⢠22h â˘
đ¤ Fujirebio is excited to join the AD-RIDDLE project, a groundbreaking hashtag#collaboration between 24 partners to bridge the gap between hashtag#Alzheimerâs research, implementation science, and precision medicine â¤ď¸ "